HOME RESEARCH PUBLICATIONS WORKSHOPS FILMS APPS TALKS NEWS STAFF CONTACT ...Go Back

Chief Investigator - Prof Dame Lesley Fallowfield

Co-Investigator - Prof Val Jenkins

Funder: Hoffman La Roche

Sponsor: Hoffman La Roche

PrefHer

PrefHer was an industry-funded, multi-centre study, examining patient preference between two methods of administering an important breast cancer drug. This crossover study was conducted across 12 countries using pre- and post-treatment questionnaires to determine which method of administration patients prefer. The study evaluated the experiences and satisfaction of health care professionals with the two methods, and explored the factors influencing patient preference.

• Current Stage:

  Archived

• Publication

  Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: final analysis of the randomized, two-cohort PrefHer study https://doi.org/10.1016/j.ejca.2017.08.019

• Publication

  Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study https://doi.org/10.1016/j.breast.2015.01.002

• Publication

  Patient preference for subcutaneous versus intravenous administration of trastuzumab in patients with early breast cancer (PrefHer study): a phase 2 randomised, multicenter, international trial https://doi.org/10.1016/S1470-2045(13)70383-8

• Publication

  Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial https://doi.org/10.1016/j.breast.2017.05.004

• Publication

  Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, twocohort PrefHer study https://doi.org/10.1093/annonc/mdu364

• Publication

  Intravenous versus Subcutaneous Drug Administration. Which do Patients Prefer? A Systematic Review https://doi.org/10.1007/s40271-014-0075-y

• Poster

  PATIENT PREFERENCE FOR SUBCUTANEOUS VERSUS INTRAVENOUS ADJUVANT TRASTUZUMAB: RESULTS OF THE PREFHER STUDY posters/Pivot et al StGallen2013 207 final.pdf
Presented at St Gallen International Breast Cancer Conference 2013

• Poster

  Reasons for patients' preferences for subcutaneous or intravenous trastuzumab in the PrefHer study posters/Fallowfield_PrefHer_Patients_ECC_poster_FINAL.pdf

• Poster

  Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study posters/PrefHer ESMO Oct 2016.pdf
Presented at European Society for Medical Oncology (ESMO) conference 2016

• Patient Information Film

  PrefHer Training and Information DVD

• Patient Information Film

  Herceptin Trastuzamab

• Patient Information Film

  PrefHer Training DVD

EMAIL: adminshore-c@sussex.ac.uk PHONE: 01273 873019 TWITTER: https://twitter.com/SussexSHORE_C LOCATION: MAP